- Frederiksborggade 15
- 1360 København K
- Dänemark
- +45 88745263
- copenhagen@eib.org
Kontakt
Weitere Pressemitteilungen
Denmark: IO Biotech secures up to €57.5 million EIB venture debt to advance cancer vaccine research and development.
Danish med-tech company IO Biotech has signed a €57.5 million venture debt deal with the European Investment Bank. The debt facility includes three committed tranches totalling up to €37.5 million, which will become available if the company satisfies certain conditions, and one uncommitted accordion tranche of €20 million. The clinical-stage biopharmaceutical company is developing novel, immune-modulating cancer vaccine therapies based on an innovative proprietary technology platform. The company will mainly use the financing for the development and market launch of IO102-IO103, an immunotherapeutic cancer vaccine to treat melanoma, with a view to employing the vaccine more broadly against other types of cancer. The EIB financing is supported by the European Commission’s InvestEU programme.
Dänemark: Norlase erhält von der EIB 20 Mio. Euro als Venture Debt für neueste Augenlaser-Technologie
Das Medtech-Unternehmen Norlase hat mit der Europäischen Investitionsbank (EIB) eine Venture-Debt-Finanzierung über 20 Millionen Euro unterzeichnet. Die Finanzierung soll das Spin-out der Technischen Universität Dänemark bei Investitionen in seine innovative Augenlaser-Technologie unterstützen und wird Dänemarks Position als Innovations-Hub von Weltrang für Medizintechnik stärken. Europäische Unternehmen, die Schlüsseltechnologien entwickeln, müssen in der EU das nötige Wachstumskapital erhalten. Dafür muss Europa sorgen, um seine strategische Autonomie zu sichern. Die Finanzierung der EIB wird über das InvestEU-Programm der Europäischen Kommission gefördert.
Danish companies ahead in digital domain, EIB Investment Survey shows
Danish businesses have done more than most in Europe to embrace digital technologies, according to a European Investment Bank (EIB) Group survey. More than four-fifths of Danish firms – 84% – have acted in this field compared with a 74% average in the European Union, new country results from the EIB Group Investment Survey (EIBIS) show.